The Research and Findings Of Oncotarget

Alzheimer’s disease is known as being a progressive degenerative disease that has been mainly diagnosed by clinical features that include the progressive impairment of cognitive orientation, function, language disturbance, motor activity and difficulty with identifying and recognizing persons and objects. Some of the histopathological hallmarks of Alzheimer’s disease includes neurofibrillary tangles and senile plaques that are obtained respectively by the deposition by the hyperohosphorylated Tau protein and aggregated amyloid peptide. The prevalence of Alzheimer’s diseases that has progressively increased throughout the world’s population. There are thirty-five million people that have been considered to be affected by Alzheimer’s Diseases and it is expected that this number will double over the next few decades. An increase in the incidence of obesity has also been observed over the last few years. It has been shown that obesity is the most common nutritional disorder in countries with developed statuses. In fact, there have been some studies that have shown obesity to be associated with a reduced cognitive performance within humans, as well as a decrease in brain volumes, and has also been correlated in increased probabilities in developing a cognitive decline, including Alzheimer’s diesease.

A high fat diet is a main factor that could promote obesity and previous studies, in rodents this has been shown to produce memory and learning impairments.The materials and methods that were used for this study were Mice, Glucose, Insulin and Insulin Tolerance Tests, Western Blotting and Total Protein Extraction and Insoluble Brain Fractions and Preparation of Soluble. Also included was Nuclear Protein Extracts and Preparation of Cytoplasmic, Immunomorphological Analyses: Immunohistochemistry and Immunofluorescence, Quantitative Real-Time qPCR, RT2 ProfilerPCR Array and Statistical Analysis. Results included the effects on the high fat diet on Body and Brain Weights, Alzheimer’s diesease markers increase in Brains from High Fat Diet versus Control Fed Mice and High Fat Diet Fed Mice Showing Insulin Resistance. In conclusion, it was shown that preventing the metabolic and cellular dysfunctions common to both obesity and Alzheimer’s diesease may not just attenuate pathological events with the peripheral organs, but also those of the brain.

At a University of the Rochester Medical Center has suggested that the electronic cigarettes are equally as damaging to the teeth and gums as the effects of conventional cigarettes. The study that was published by Oncotarget, was the first study in addressing e-cigarettes and the detrimental effects on oral health in molecular and cellular levels. In had been shown previously that scientist have thought that chemicals that are found in cigarette smoke are the culprits in adverse health effects. This was included in the growing body of the scientific data, which includes the current study.During the study, that included an exposed 3-D human, including non-smoker gum tissue with the vapors of e-cigarettes. And through this found that the flavored chemicals have played a role on damaging cells within the mouth. Most of the e-cigarettes contain a battery, cartridge for holding liquid and a battery. This typically includes flavorings, nicotine and other chemicals. And the battery powered device heats the liquid in the cartridge into aerosol that in turn the user inhales.

Scientific Expert Researcher, Mikhail Blagosklonny on Cancer, Aging and Immunity

The Professor of Oncology at Roswell Park Cancer Center, Mikhail Blagosklonny, has been able to create and come up with new scientific findings. His research has enabled him to get recommendations on how to approach the menace that cancer has caused. The treatments that he has come with being able to treat cancer decisively with other benefits that go with it. Drugs curing cancer are also able to rejuvenate skin.

Mikhail Blagosklonny went to the First Pavlov State Medical University in St Petersburg where he got his MD in Internal Medicine. The Ph. D that he has in Experimental Medicine and Cardiology is from the same University.

Mikhail Blagosklonny started off his career when he was employed by New York Medical College as an associate professor of medicine. He later went to Ordway Research Institute serving as a Senior Research Scientist. Roswell Park Center made him an Oncologist Professor in 2009. The ingenuity that he has led to solving of cancer in a less damaging manner. He concerns himself in fields like looking for drugs that will replace the therapies that are used today. His means do not damage healthy cells. Biogerontology is also an area of concern to him whereby he tries to explain why we get old. View Mikhail’s profile in LinkedIn

Mikhail Blagosklonny is now the editor-in-chief of Oncotarget and Cell Cycle. Blagosklonny is a co-editor who focuses on cancer biology and cancer therapy. He is a board member of the editorial board of Cell Death and Differentiation. The board seeks answers to questions that are about TOR signaling potential that the board says has an effect on cancer and aging. His invention, Rapamycin is a new drug that is yet to be released. The research shows that the drug can cure cancer and also age. With his team, he believes they can use the drug to also boost immunity in the people who are aging.

Mikhail research also consists of topics in Cellular and Molecular Biology and Clinical investigations. Articles were written are on aging hyperfunction theory, technology on chemotherapeutic engineering and cell cyclotherapy. Studies and research are on cell cycles, apoptosis, signal transduction, ontogenesis, and cancer tumor suppressors, resistance to drugs, selective protection, anticancer therapeutics and mitosis. The bottom-line is that the drug, Rapamycin is going to be the discovery of the century and will treat cancer.

Read more:

In his work of writing articles, he has been able to write over 300 pieces. The journals and book chapters are in his agendas. He has printed and published the articles under his name. On top of all this, he is an associate editor at PLOS ONE who is an American Journal of Pathology and is also editing at the International Journal of Cancer. Mikhail’s commitment and efforts that have had stamina have made lots of achievements that will benefit all the people around the globe. The studies carried out can be improved by the younger generations that are in the scientific world so as to give enhanced solutions for treating cancer.